It seems like a century since I last heard anything about Intarcia. We discussed it quite a bit years ago. Relative patent infringement positions vis a vis Amylin and Exenatide, as I recall. Now AZN in control of Exenatide diabetes assets once-jointly owned with BMY?
Market Data 
Markets 
AI
